Changing the regulations: Hope dies last. [NCA / SHAM]

posted by PharmCat  – Russia, 2021-10-01 20:48 (1303 d 12:55 ago) – Posting: # 22613
Views: 4,480

❝ Hhm, can you elaborate?


these are my thoughts, I did not support them with any deep search ...
$$C = C_0 * e^{-k_e * t}$$ => $$C = \frac{D}{V_d} * e^{-k_e * t}$$
Model:
$$C = \frac{aX + \epsilon_2}{V_d} * e^{-bZ * t} * \epsilon_1 $$
$$ \epsilon_1 \sim N(0, \sigma_1^2); \epsilon_2 \sim N(0, \sigma_2^2)$$
It can be solved for \(a, V_d, b, \sigma_1^2, \sigma_2^2\) and modified for extravascular model.

Something described here: Korkmaz, Selcuk & Orman, Mehmet. (2012). The Use of Nonlinear Mixed Effects Models in Bioequivalence Studies: A Real Data Application. Open Access Scientific Reports. 1-11

However, I think terminal-phase adjusted area under the concentration curve method is something between the classic and NLME approaches. And both of them make corrections for variation from elimination.

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,668 registered users;
29 visitors (0 registered, 29 guests [including 10 identified bots]).
Forum time: 09:44 CEST (Europe/Vienna)

It is true that many scientists are not philosophically minded
and have hitherto shown much skill and ingenuity
but little wisdom.    Max Born

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5